Beta-adrenergic signaling in the development and progression of pulmonary and pancreatic adenocarcinoma

Current Cancer Therapy Reviews

Volumn 8, Issue 2, 2012, Pages 116-127

  Schuller, Hildegard M ^a   Al Wadei, Hussein A N ^a,b  

^a Department of Comparative Medicine   (United States)

^b SANA A UNIVERSITY   (Yemen)

Author keywords

Adenocarcinoma; Beta adrenergic signaling; GABA; Lung; Pancreas

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ADENYLATE CYCLASE; ADRENALIN; ALPHA TOCOPHEROL; BACLOFEN; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; CAFFEINE; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR; FORSKOLIN; ISOPRENALINE; LIPOXYGENASE INHIBITOR; NEUROTRANSMITTER; NICOTINE; NICOTINIC RECEPTOR; NORADRENALIN; PROPRANOLOL; THEOPHYLLINE; TOBACCO SMOKE; UNINDEXED DRUG; VASCULOTROPIN;

ALCOHOLISM; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL ASSESSMENT; DRUG EFFICACY; DRUG INHIBITION; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; MENTAL STRESS; NEUROTRANSMISSION; NITROSATION; NONHUMAN; PANCREAS ADENOCARCINOMA; PATHOPHYSIOLOGY; PHARMACOLOGIC STRESS TESTING; PREVALENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT;

EID: 84861789393     PISSN: 15733947     EISSN: 18756301     Source Type: Journal    
DOI: 10.2174/157339412800675351     Document Type: Review

References (125)

1. Einhorn LH, Bonomi P, Bunn PA, et al. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol 2008; 3(5): 545-55.
2. Almhanna K, Philip PA. Defining New Paradigms for the Treatment of Pancreatic Cancer. Curr Treat Options Oncol 2011; 12(2): 111-25.
3. Hoffmann D, Rivenson A, Chung FL, Hecht SS. Nicotine-derived N-nitrosamines (TSNA) and their relevance in tobacco carcinogenesis. Crit Rev Toxicol 1991; 21(4): 305-11.
4. Schuller HM, Witschi HP, Nylen E, Joshi PA, Correa E, Becker KL. Pathobiology of lung tumors induced in hamsters by 4 (methylnitrosamino)-1-(3-pyridyl)-1-butanone and the modulating effect of hyperoxia. Cancer Res 1990; 50(6): 1960-5.
5. Rivenson A, Hoffmann D, Prokopczyk B, Amin S, Hecht SS. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res 1988; 48(23): 6912-7.
6. Schuller HM, Jorquera R, Reichert A, Castonguay A. Transplacental induction of pancreas tumors in hamsters by ethanol and the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3pyridyl)-1-butanone. Cancer Res 1993; 53(11): 2498-501.
7. Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer 2009; 9(3): 195-205.
8. Gao HG, Chen JK, Stewart J, et al. Distribution of p53 and K-ras mutations in human lung cancer tissues. Carcinogenesis 1997; 18(3): 473-8.
9. Koliopanos A, Avgerinos C, Paraskeva C, Touloumis Z, Kelgiorgi D, Dervenis C. Molecular aspects of carcinogenesis in pancreatic cancer. Hepatobiliary Pancreat Dis Int 2008; 7(4): 345-56.
10. Hecht SS. DNA adduct formation from tobacco-specific Nnitrosamines. Mutat Res 1999; 424(1-2): 127-42.
11. Soto AM, Sonnenschein C. The somatic mutation theory of cancer: growing problems with the paradigm? Bioessays 2004; 26(10): 1097-107.
12. Sato M, Vaughan MB, Girard L, et al. Multiple oncogenic changes (K-Ras(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 2006; 66(4): 2116-28.
13. Kim D, Steward MC. The role of CFTR in bicarbonate secretion by pancreatic duct and airway epithelia. J Med Invest 2009; 56 (Suppl): 336-42.
14. Van Scott MR, Penland CM, Welch CA, Lazarowski E. Betaadrenergic regulation of Cland HCO3secretion by Clara cells. Am J Respir Cell Mol Biol 1995; 13(3): 344-51.
15. Novak I. beta-Adrenergic regulation of ion transport in pancreatic ducts: patch-clamp study of isolated rat pancreatic ducts. Gastroenterology 1998; 115(3): 714-21.
16. Majidi M, Al-Wadei HA, Takahashi T, Schuller HM. Nongenomic beta estrogen receptors enhance beta1 adrenergic signaling induced by the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3pyridyl)-1-butanone in human small airway epithelial cells. Cancer Res 2007; 67(14): 6863-71.
17. Al-Wadei HA, Al-Wadei MH, Masi T, Schuller HM. Chronic exposure to estrogen and the tobacco carcinogen NNK cooperatively modulates nicotinic receptors in small airway epithelial cells. Lung Cancer 2009; 69(1): 33-9.
18. Askari MD, Tsao MS, Schuller HM. The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors. J Cancer Res Clin Oncol 2005; 131(10): 639-48.
19. Askari MD, Tsao MS, Cekanova M, Schuller HM. Ethanol and the tobacco-specific carcinogen, NNK, contribute to signaling in immortalized human pancreatic duct epithelial cells. Pancreas 2006; 33(1): 53-62.
20. Schuller HM, Tithof PK, Williams M, Plummer H, 3rd. The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl) 1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptormediated release of arachidonic acid. Cancer Res 1999; 59(18): 4510-5.
21. Schuller HM, Cole B. Regulation of cell proliferation by betaadrenergic receptors in a human lung adenocarcinoma cell line. Carcinogenesis 1989; 10(9): 1753-5.
22. Laag E, Majidi M, Cekanova C, Masi T, Takahashi T, Schuller HM. NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. Int J Cancer 2006; 119(7): 1547-52.
23. Schuller HM, Al-Wadei HA, Majidi M. Gamma-aminobutyric acid, a potential tumor suppressor for small airway-derived lung adenocarcinoma. Carcinogenesis 2008; 29(10): 1979-85.
24. Weddle DL, Tithoff P, Williams M, Schuller HM. Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis 2001; 22(3): 473-9.
25. Schuller HM, Al-Wadei HA, Majidi M. GABA B receptor is a novel drug target for pancreatic cancer. Cancer 2008; 112(4): 767-78.
26. Schuller HM, Porter B, Riechert A. Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters. J Cancer Res Clin Oncol 2000; 126(11): 624-30.
27. Al-Wadei HA, Schuller HM. Nicotinic receptor-associated modulation of stimulatory and inhibitory neurotransmitters in NNK-induced adenocarcinoma of the lungs and pancreas. J Pathol 2009; 218(4): 437-45.
28. Al-Wadei HA, Al-Wadei MH, Schuller HM. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs 2009.
29. Schuller HM. Carbon dioxide potentiates the mitogenic effects of nicotine and its carcinogenic derivative, NNK, in normal and neoplastic neuroendocrine lung cells via stimulation of autocrine and protein kinase C-dependent mitogenic pathways. Neurotoxicology 1994; 15(4): 877-86.
30. Schuller HM, Miller MS, Park PG, Orloff MS. Promoting mechanisms of CO2 on neuroendocrine cell proliferation mediated by nicotinic receptor stimulation. Significance for lung cancer risk in individuals with chronic lung disease. Chest 1996; 109(3 Suppl):20S-1S.
31. Schuller HM, McGavin MD, Orloff M, Riechert A, Porter B. Simultaneous exposure to nicotine and hyperoxia causes tumors in hamsters. Lab Invest 1995; 73(3): 448-56.
32. Purdue MP, Gold L, Jarvholm B, Alavanja MC, Ward MH, Vermeulen R. Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers. Thorax 2007; 62(1): 51-6.
33. Belinsky SA, Devereux TR, White CM, Foley JF, Maronpot RR, Anderson MW. Role of Clara cells and type II cells in the development of pulmonary tumors in rats and mice following exposure to a tobacco-specific nitrosamine. Exp Lung Res 1991; 17(2): 263-78.
34. Belinsky SA, Devereux TR, Anderson MW. Role of DNA methylation in the activation of proto-oncogenes and the induction of pulmonary neoplasia by nitrosamines. Mutat Res 1990; 233(1-2): 105-16.
35. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91(14): 1194-210.
36. Schuller HM, Cekanova M. NNK-induced hamster lung adenocarcinomas over-express beta2-adrenergic and EGFR signaling pathways. Lung Cancer 2005; 49(1): 35-45.
37. El-Bayoumy K, Iatropoulos M, Amin S, Hoffmann D, Wynder EL. Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4 (methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet. Cancer Res 1999; 59(7): 1400-3.
38. Razani-Boroujerdi S, Sopori ML. Early manifestations of NNKinduced lung cancer: role of lung immunity in tumor susceptibility. Am J Respir Cell Mol Biol 2007; 36(1): 13-9.
39. Yamaki T, Yano T, Satoh H, et al. High oleic acid oil suppresses lung tumorigenesis in mice through the modulation of extracellular signal-regulated kinase cascade. Lipids 2002; 37(8): 783-8.
40. Schuller HM, Orloff M. Tobacco-specific carcinogenic nitrosamines. Ligands for nicotinic acetylcholine receptors in human lung cancer cells. Biochem Pharmacol 1998; 55(9): 1377-84.
41. Park PG, Merryman J, Orloff M, Schuller HM. Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res 1995; 55(16): 3504-8.
42. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117(2): 294-9.
43. Grau M, Soley M, Ramirez I. Interaction between adrenaline and epidermal growth factor in the control of liver glycogenolysis in mouse. Endocrinology 1997; 138(6): 2601-9.
44. Jin Z, Xin M, Deng X. Survival function of protein kinase C{iota} as a novel nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1butanone-activated bad kinase. J Biol Chem 2005; 280(16): 16045-52.
45. West KA, Brognard J, Clark AS, et al. Rapid AKT activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003; 111: 81-90.
46. Al-Wadei HA, Takahasi T, Schuller HM. PKA-dependent growth stimulation of cells derived from human pulmonary adenocarcinoma and small airway epithelium by dexamethasone. Eur J Cancer 2005; 41(17): 2745-53.
47. Al-Wadei HA, Takahashi T, Schuller HM. Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer 2006; 118(6): 1370-80.
48. Al-Wadei HA, Schuller HM. Cyclic adenosine monophosphatedependent cell type-specific modulation of mitogenic signaling by retinoids in normal and neoplastic lung cells. Cancer Detect Prev 2006; 30(5): 403-11.
49. Al-Wadei HA, Takahashi T, Schuller HM. Caffeine stimulates the proliferation of human lung adenocarcinoma cells and small airway epithelial cells via activation of PKA, CREB and ERK1/2. Oncol Rep 2006; 15(2): 431-5.
50. Al-Wadei HAN, Takahashi T, Schuller HM. Theophylline stimulates cAMP-mediated signaling associated with growth regulation in human cells from pulmonary adenocarcinoma and small airway epithelia. Int J Oncol 2005; 27: 27-155.
51. Al-Wadei HAN, Al-Wadei MH, Ullah MF, Schuller HM. Gammaaminobutyric acid inhibits the nicotine-imposed stimulatory challenge in xenograft models of non small cell lung carcinoma. Curr Cancer Drug Targets 2012; 12(2): 97-106.
52. Al-Wadei HA, Schuller HM. Beta-Carotene promotes the development of NNK-induced small airway-derived lung adenocarcinoma. Eur J Cancer 2009; 45(7): 1257-64.
53. Schuller HM, Porter B, Riechert A, Walker K, Schmoyer R. Neuroendocrine lung carcinogenesis in hamsters is inhibited by green tea or theophylline while the development of adenocarcinomas is promoted: implications for chemoprevention in smokers. Lung Cancer 2004; 45(1): 11-8.
54. Goralczyk R, Wertz K, Lenz B, et al. Beta-carotene interaction with NNK in the AJ-mouse model: effects on cell proliferation, tumor formation and retinoic acid responsive genes. Biochim Biophys Acta 2005; 1740(2): 179-88.
55. Chung FL. The prevention of lung cancer induced by a tobaccospecific carcinogen in rodents by green and black Tea. Proc Soc Exp Biol Med 1999; 220(4): 244-8.
56. Adissu HA, Schuller HM. Antagonistic growth regulation of cell lines derived from human lung adenocarcinomas of Clara cell and aveolar type II cell lineage: Implications for chemoprevention. Int J Oncol 2004; 24(6): 1467-72.
57. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res 2000; 886(1-2): 172-89.
58. Hu W, Zhang M, Czéh B, Flügge G, Zhang W. Stress impairs GABAergic network function in the hippocampus by activating nongenomic glucocorticoid receptors and affecting the integrity of the parvalbumin-expressing neuronal network. Neuropsychopharmacology 2010; 35: 1693-707.
59. Elizalde N, García-García AL, Totterdell S, et al. Sustained stressindeuced changes in mice as a model for chronic depression. Psychopharmacology 2010; 210(3): 393-406.
60. Al-Wadei HAN, Plummer HK 3rd, Ullah MF, Unger B, Brody J, Schuller HM. Social stress promotes and -aminobutyric acid prevents the growth of non small cell lung cancer. Cancer Prev Res (Phila) 2012; 5(2): 189-96
61. Sood AK, Bhatty R, Kamat AA, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006; 12(2): 369-75.
62. Ben-Eliyahu S, Shakhar G, Page GG, Stefanski V, Shakhar K. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoreceptors. Neuroimmunomodulation 2000; 8(3): 154-64.
63. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 2001; 31(2-3): 139-48.
64. Harris RE, Zang EA, Anderson JI, Wynder EL. Race and sex differences in lung cancer risk associated with cigarette smoking. Int J Epidemiol 1993; 22(4): 592-9.
65. Xie Y, Minna JD. Predicting the future for people with lung cancer. Nat Med 2008; 14(8): 812-3.
66. Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology 2001; 10(1): 19-28.
67. Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol 1999; 149(1): 13-20.
68. Adcock IM, Caramori G, Barnes PJ. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration 2011; 81(4): 265-84.
69. Wang XR, Yu IT, Chiu YL, et al. Previous pulmonary disease and family cancer history increase the risk of lung cancer among Hong Kong women. Cancer Causes Control 2009; 20(5): 757-63.
70. Aksoy MO, Mardini IA, Yang Y, Bin W, Zhou S, Kelsen SG. Glucocorticoid effects on the beta-adrenergic receptor-adenylyl cyclase system of human airway epithelium. J Allergy Clin Immunol 2002; 109(3): 491-7.
71. Giembycz MA, Field SK. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 2010; 4: 147-58.
72. Lang K, Drell TLt, Lindecke A, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004; 112(2): 231-8.
73. Palm D, Lang K, Niggemann B, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006; 118(11): 2744-9.
74. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334(18): 1150-5.
75. Brodkin CA, McCullough J, Stover B, et al. Lobe of origin and histologic type of lung cancer associated with asbestos exposure in the Carotene and Retinol Efficacy Trial (CARET). Am J Ind Med 1997; 32(6): 582-91.
76. Albanes D, Heinonen OP, Taylor PR, et al. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alphatocopherol, beta-carotene cancer prevention study: effects of baseline characteristics and study compliance. J Natl Cancer Inst 1996; 88(21): 1560-70.
77. Algazi M, Plu-Bureau G, Flahault A, Dondon MG, Le MG. [Could treatments with beta-blockers be associated with a reduction in cancer risk?]. Rev Epidemiol Sante Publique 2004; 52(1): 53-65.
78. Peeters PH, van Noord PA, Hoes AW, Grobbee DE. Hypertension, antihypertensive drugs, and mortality from cancer among women. J Hypertens 1998; 16(7): 941-7.
79. Assimes TL, Elstein E, Langleben A, Suissa S. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf 2008; 17(11): 1039-49.
80. Friedman GD, Jiang SF, Udaltsova N, Quesenberry CP Jr., Chan J, Habel LA. Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity. Int J Cancer 2009; 125(9): 2173-8.
81. Shah SM, Carey IM, Owen CG, Harris T, Dewilde S, Cook DG. Does beta-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 2011; 72(1): 157-61.
82. Powe DG, Voss MJ, Zanker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1(7): 628-38.
83. Shafer SH, Phelps SH, Williams CL. Reduced DNA synthesis and cell viability in small cell lung carcinoma by treatment with cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol 1998; 56(9): 1229-36.
84. Plummer HK 3rd, Dhar MS, Cekanova M, Schuller HM. Expression of G-protein inwardly rectifying potassium channels (GIRKs) in lung cancer cell lines. BMC Cancer 2005; 5: 104.
85. Al-Wadei HA, Schuller HM. Non-genomic inhibitory signaling of beta-carotene in squamous cell carcinoma of the lungs. Int J Oncol 2009; 34(4): 1093-8.
86. Droms KA. Beta-adrenergic signalling in neoplastic lung type 2 cells: glucocorticoid-dependent and -independent defects. Br J Cancer 1996; 74(3): 432-8.
87. Nakane T, Szentendrei T, Stern L, Virmani M, Seely J, Kunos G. Effects of IL-1 and cortisol on beta-adrenergic receptors, cell proliferation, and differentiation in cultured human A549 lung tumor cells. J Immunol 1990; 145(1): 260-6.
88. Kamholz SL. Wine, spirits and the lung: good, bad or indifferent? Trans Am Clin Climatol Assoc 2006; 117: 129-45.
89. Pereira GE, Gaidillere JP, Pieri P, et al. Microclimate influence on mineral and metabolic profiles of grape berries. J Agric Food Chem 2006; 54(18): 6765-75.
90. Pavoine C, Magne S, Sauvadet A, Pecker F. Evidence for a beta2adrenergic/arachidonic acid pathway in ventricular cardiomyocytes. Regulation by the beta1-adrenergic/camp pathway. J Biol Chem 1999; 274(2): 628-37.
91. Al-Wadei HA, Majidi M, Tsao MS, Schuller HM. Low concentrations of beta-carotene stimulate the proliferation of human pancreatic duct epithelial cells in a PKA-dependent manner. Cancer Genomics Proteomics 2007; 4(1): 35-42.
92. Schuller HM, Al-Wadei HA, Majidi M. GABA(B) receptor is a novel drug target for pancreatic cancer. Cancer 2008; 112(4): 767-78.
93. Zhang D, Ma QY, Hu HT, Zhang M. Beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkappaB and AP-1. Cancer Biol Ther 2010; 10(1): 19-29.
94. Guo K, Ma Q, Wang L, et al. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 2009; 22(4): 825-30.
95. Zhang D, Ma Q, Shen S, Hu H. Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell. Pancreas 2009; 38(1): 94-100.
96. Al-Wadei MH, Al-Wadei HAN, Schuller HM. Pancreatic cancer cells and their cells of origin express an autocrine catecholamine loop that is actvated by the 7 nicotinic acetylcholine receptor. Molec Cancer Res 2012; 10(2): 239-249.
97. Chipitsyna G, Gong Q, Anandanadesan R, et al. Induction of osteopontin expression by nicotine and cigarette smoke in the pancreas and pancreatic ductal adenocarcinoma cells. Int J Cancer 2009; 125(2): 276-85.
98. Lazar M, Sullivan J, Chipitsyna G, et al. Involvement of osteopontin in the matrix-degrading and proangiogenic changes mediated by nicotine in pancreatic cancer cells. J Gastrointest Surg 2010; 14(10): 1566-77.
99. Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K, Miller MS. The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol 2002; 128(10): 525-32.
100. Adachi T, Tajima Y, Kuroki T, et al. Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters. Carcinogenesis 2008; 29(4): 830-3.
101. Wendt LR, Osvaldt AB, Bersch VP, Schumacher Rde C, Edelweiss MI, Rohde L. Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice: effects of alcohol and caffeine. Acta Cir Bras 2007; 22(3): 202-9.
102. Al-Wadei HA, Plummer HK 3rd, Schuller HM. Nicotine stimulates pancreatic cancer xenografts by systemic increase in stress neurotransmitters and suppression of the inhibitory neurotransmitter gamma-aminobutyric acid. Carcinogenesis 2009; 30(3): 506-11.
103. Haass M, Kubler W. Nicotine and sympathetic neurotransmission. Cardiovasc Drugs Ther 1997; 10(6): 657-65.
104. Fowler ML, Sigler RE, de la Iglesia FA, Reddy JK, Lalwani ND. Absence of Ki-ras mutations in exocrine pancreatic tumors from male rats chronically exposed to gabapentin. Mutat Res 1995; 327(1-2): 151-60.
105. Sigler RE, Gough AW, de la Iglesia FA. Pancreatic acinar cell neoplasia in male Wistar rats following 2 years of gabapentin exposure. Toxicology 1995; 98(1-3): 73-82.
106. Shimizu S, Honda M, Tanabe M, Ono H. GABAB receptors do not mediate the inhibitory actions of gabapentin on the spinal reflex in rats. J Pharmacol Sci 2004; 96(4): 444-9.
107. Takasu K, Ono H, Tanabe M. Gabapentin produces PKAdependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice. J Neurochem 2008; 105(3): 933-42.
108. Takehara A, Hosokawa M, Eguchi H, et al. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res 2007; 67(20): 9704-12.
109. Schuller HM, Al-Wadei HAN, Ullah MF, PlummerII. HK. Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention. Carcinogeneisi 2012; 33(1): 191-196.
110. Lowenfels AB, Maisonneuve P. Risk factors for pancreatic cancer. J Cell Biochem 2005; 95(4): 649-56.
111. Silverman DT. Risk factors for pancreatic cancer: a case-control study based on direct interviews. Teratog Carcinog Mutagen 2001; 21(1): 7-25.
112. Al-Salam S, Hameed R, Parvez HS, Adeghate E. Diabetes mellitus decreases the expression of calcitonin-gene related peptide, gamma-amino butyric acid and glutamic acid decarboxylase in human pancreatic islet cells. Neuro Endocrinol Lett 2009; 30(4): 506-10.
113. Schrader H, Menge BA, Belyaev O, Uhl W, Schmidt WE, Meier JJ. Amino acid malnutrition in patients with chronic pancreatitis and pancreatic carcinoma. Pancreas 2009; 38(4): 416-21.
114. Buscher HC, van Goor H, Sweep CG, Lenders JW, Wilder-Smith OH. Increased sympathetic activity in chronic pancreatitis is associated with hyperalgesia. J Pail Palliat Care Pharmacother 2010; 24(4): 362-6.
115. Braganza JM, Lee SH, McCloy RF, McMahon MJ. Chronic pancreatitis. Lancet; 377(9772): 1184-97.
116. Michel MC, Pingsmann A, Beckeringh JJ, Zerkowski N, Doetsch N, Brodde OE. Selective regulation of beta 1-and beta 2adreneoreceptors in the human heart by chronic betaadreneoreceptor antagonist treatment. Br J Pharmacol 1988; 94(3): 685-92.
117. Brodde OE, Daul A, Michel MC. Subtype-selective modulation of human beta 1-and beta 2-adrenoreceptor function by betaadrenoreceptor agonists and antagonists. Clin Physiol Biochem 1990; 8 (Suppl 2): 11-7.
118. Hamer M, Chida Y, Molloy GJ. Psychological distress and cancer mortality. J Psychosom Res 2009; 66(3): 255-8.
119. Paleari L, Catassi A, Servent D, et al. Inhibition of non-neuronal alpha7-nicotinic receptor reduces tumorigenicity in A549 NSCLC xenografts. Int J Cancer 2009; 125(1): 199-211.
120. Bown AW, Macgregor KB, Shelp BJ. Gamma-aminobutyrate: defense against invertebrate pests? Trends Plant Sci 2006; 11(9): 424-7.
121. OH CH, OH SH. Effects of germinated brown rice extracts with enhanced levels of GABA on cancer cell proliferation and apoptosis. J Med Food 2004; 7(1): 18-23.
122. Akama K, Kanetou J, Shimosaki S, Kawakami K, Tsuchikura S, Takaiwa F. Seed-specific expression of truncated OsGAD2 produces GABA-enriched rice grains that influence a decrease in blood pressure in spontaneously hypertensive rats. Transgenic Res 2009; 18(6): 865-76.
123. Hayakawa K, Kimura M, Kasaha K, Matsumoto K, Sansawa H, Yamori Y. Effect of a gamma-aminobutyric acid-enriched dairy product on the blood pressure of spontaneously hypertensive and normotensic Wistar-Kyoto rats. Br J Nutr 2004; 92: 411-7.
124. Schuller HM. Neurotransmission and cancer: implications for prevention and therapy. Anticancer Drugs 2008; 19(7): 655-71.
125. Powe DG, Voss MJ, Zanker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1(7): 628-38.